ClinicalTrials.gg
Not yet recruitingNCT07943026TAILORUpdated Nov 17, 2026

Personalized Antiplatelet Therapy to Prevent Recurrent Cardiovascular Events in After Ischemic Stroke

A Phase 4 interventional study of Acetylsalicylic acid (ASA)/aspirin 100 mg daily and Clopidogrel 75 mg daily in Ischemic Stroke, sponsored by Azienda Usl di Bologna. Not yet recruiting at 3 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Azienda Usl di Bologna · Phase 4, Interventional, and Prevention

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,506
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 81 studies in Ischemic Stroke with a site in Italy — 23 open to participants now, 29 under way, 2 of them phase 3. Ischemic Stroke · Italy.

Planned enrollment
10th of 50
1,506 · median 227
Started
2026
with 2 others
Phase 4
5 of 81
1 open now
Primary completion
2029-12
later than 26 of 28 live
Registered
81st of 81
by date
Lead sponsor
4 of 81
Azienda Usl di Bologna

Among the 81 studies in Ischemic Stroke with a site in Italy, this one is the 10th largest by planned enrollment of the 50 interventional ones that give a count, is one of 3 that started in 2026, is one of 5 in phase 4, reaches primary completion later than 26 of the 28 other live ones, and was the 81st registered.

Ischemic Stroke

2,619 studies on the registry are indexed under Ischemic Stroke; 978 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

23 of the 81 studies in Ischemic Stroke with a site in Italy are open now. Recruiting first, the newest first:

17 more — sign in →

All 23 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 662 Ischemic Stroke studies recruiting now, 396 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 26 take children under 18; 42 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Ischemic Stroke with a site in Italy, or all of them as a file.
02

Study summary

The TAILOR study aims to determine whether personalized antiplatelet therapy can reduce the risk of recurrent major cardiovascular events in patients who have experienced (a non-cardioembolic ischemic stroke).

Antiplatelet medications, such as aspirin and clopidogrel, are commonly prescribed to prevent stroke recurrence. However, some patients do not respond adequately to these medications and may remain at increased risk of further cardiovascular events.

The study will compare two approaches to antiplatelet therapy: standard care, in which medications are prescribed according to current clinical practice, and personalized care (tailored care), in which treatment is adjusted based on a blood test measuring how effectively the medication inhibits platelet activity.

Participants will be randomly assigned to one of these two treatment strategies and followed for 12 months.

The main hypothesis is that tailoring antiplatelet therapy according to individual platelet response will be more effective than standard care in preventing recurrent ischemic stroke, myocardial infarction, or cardiovascular death. The study will also explore potential differences in treatment response between women and men.

Read the detailed description

Antiplatelet therapy is a cornerstone of secondary prevention following non-cardioembolic ischemic stroke. However, a substantial proportion of patients experience recurrent cardiovascular events despite receiving guideline-recommended antiplatelet treatment. One potential explanation is inadequate biological response to antiplatelet agents, commonly referred to as antiplatelet resistance. Previous observational studies have suggested that reduced responsiveness to aspirin or clopidogrel is associated with an increased risk of recurrent vascular events.

In current clinical practice, antiplatelet medications are generally prescribed without routinely assessing individual platelet response. Platelet function testing may provide an opportunity to personalize antiplatelet therapy by identifying patients with inadequate pharmacological response and guiding treatment adjustments. Furthermore, biological sex may influence antiplatelet responsiveness and treatment effectiveness, supporting the need to investigate potential sex-related differences in personalized secondary prevention strategies.

The TAILOR trial is a multicenter, phase IV, randomized, controlled, pragmatic, open-label trial with blinded endpoint assessment, designed to investigate whether antiplatelet therapy guided by platelet function testing provides greater protection against recurrent cardiovascular events than conventional antiplatelet management.

A total of 1,506 participants will be recruited across three Italian stroke centers and randomly assigned in a 1:1 ratio to a personalized antiplatelet treatment strategy (tailored care) or conventional antiplatelet management (usual care). Randomization will be performed centrally using a computer-generated allocation procedure, with balancing factors including study center, sex, baseline stroke severity, and initial antiplatelet treatment.

Participants will be enrolled within 7 days of the index ischemic stroke and will undergo a run-in period of at least 7 days of antiplatelet therapy according to usual care (10 days for patients receiving dual antiplatelet therapy). Randomization will take place within 14 days of the index event, after re-assessment of eligibility criteria at the end of the run-in period. Immediately after randomization, platelet function will be evaluated using multiple electrode aggregometry. The Multiplate Analyzer measures platelet aggregation in response to specific agonists, including arachidonic acid (ASPI test) and adenosine diphosphate (ADP test). These measurements provide information on the biological response to aspirin and clopidogrel, respectively.

In the tailored care group, antiplatelet therapy will be maintained or modified according to platelet function test results. Participants demonstrating an adequate biological response will continue their current treatment, whereas those showing insufficient platelet inhibition will be switched to an alternative approved antiplatelet agent, according to the predefined treatment algorithm.

In the usual care group, participants will continue conventional antiplatelet treatment independently of platelet function test results. Treating physicians in this group will remain unaware of the aggregometry findings.

The antiplatelet agents used in the trial include aspirin, clopidogrel, and ticlopidine, administered according to their approved indications and dosing regimens. All participants will continue to receive other appropriate secondary stroke prevention measures in accordance with current clinical guidelines.

Participants will be followed for 12 months after randomization. Clinical assessments will be conducted during follow-up, including evaluations of treatment adherence, functional status, cardiovascular events, and treatment-related safety. Endpoint assessments will be performed by personnel blinded to treatment allocation.

In addition, CYP2C19 genetic variants associated with clopidogrel metabolism will be investigated to explore their relationship with platelet responsiveness. Prespecified analyses will also examine potential differences in treatment response and clinical outcomes between female and male participants.

By integrating platelet function testing into antiplatelet treatment decisions, the TAILOR trial aims to generate evidence on the clinical value of a personalized approach to secondary stroke prevention using medications already approved and routinely available in clinical practice.

03

Conditions studied

  • Ischemic Stroke

Keywords

  • stroke
  • non-cardioembolic ischemic stroke
  • antiplatelet
  • phase IV
  • secondary prevention
  • aspirin
  • clopidogrel
  • ticlopidine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged ≥18 years old
  • Males and females
  • Non-cardioembolic ischemic stroke within the previous 14 days
  • Starting or continuing secondary prevention with single or dual antiplatelet therapy after the index stroke
  • Written .

Exclusion criteria

Exclusion Criteria:

  • Known to aspirin, clopidogrel or ticlopidine, or to any of the .
  • Concurrent need for anticoagulation for any indication
  • to study drugs
  • Indications to perform carotid revascularization surgery
  • Participation in a clinical trial in which an drug was administered within 30 days of screening or within the 5 half-lives of the study drug, whichever is longer
  • Pregnancy and breastfeeding; not using acceptable during the trial period (combined [estrogen and progestogen containing] hormonal contraception associated with inhibition of ovulation, progestogen-only hormonal contraception associated with inhibition of ovulation, intrauterine device [IUD], intrauterine hormone-releasing system [IUS], bilateral tubal occlusion. vasectomised partner, sexual abstinence, progestogen-only oral hormonal contraception, where inhibition of ovulation is not the primary mode of action, male or female condom with or without spermicide, cap, diaphragm or sponge with spermicide)
  • History of asthma induced by the administration of acetylsalicylates or substances with a similar activity, especially nonsteroidal anti-inflammatory drugs
  • Active or previous recurrent peptic ulcer and/or gastric/intestinal bleeding, or other types of bleeding such as cerebrovascular hemorrhage.
  • Bleeding diathesis; coagulation disorders such as hemophilia and thrombocytopenia.
  • Severe hepatic impairment.
  • Severe renal impairment
  • Uncontrolled severe cardiac failure
  • Methotrexate used at doses equal to or greater than 15 mg/week. Combination with other potentially myelotoxic drugs. Subjects with or who have had leukopenia, thrombocytopenia, or agranulocytosis.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
1,506 participants (estimated)

Study arms

  • Active comparator
    Usual care

    Participants in this arm will continue the antiplatelet therapy (aspirin or clopidogrel) started after the index stroke, according to usual care, independently of platelet aggregation test results. Platelet function testing is performed in all participants, but results are not disclosed to treating physicians in this arm. Patients receiving short-term DAPT will continue, at the end of the 10-day run-in period, with the single antiplatelet agent indicated by usual care (aspirin or clopidogrel), regardless of platelet aggregation test results.

    Drug: Acetylsalicylic acid (ASA)/aspirin 100 mg daily · Drug: Clopidogrel 75 mg daily · Drug: Ticlopidine 250 mg twice daily

  • Experimental
    Tailored care

    Based on platelet aggregation test results (Multiplate ASPI and ADP tests), antiplatelet therapy will be tailored as follows: 1. If taking aspirin and the test confirms responsiveness, aspirin is continued. 2. If taking clopidogrel and the test confirms responsiveness, clopidogrel is continued. 3. If taking aspirin and the test shows non-responsiveness, therapy is switched to clopidogrel or ticlopidine. 4. If taking clopidogrel and the test shows non-responsiveness, therapy is switched to aspirin or ticlopidine. Patients with an indication to short-term dual antiplatelet therapy (DAPT; minor stroke with NIHSS ≤3) will undergo a 10-day run-in period and then continue with single antiplatelet therapy: patients due to continue aspirin will switch to clopidogrel if non-responders to aspirin; patients due to continue clopidogrel will switch to ticlopidine if non-responders to clopidogrel.

    Drug: Acetylsalicylic acid (ASA)/aspirin 100 mg daily · Drug: Clopidogrel 75 mg daily · Drug: Ticlopidine 250 mg twice daily

Interventions

  • DrugAcetylsalicylic acid (ASA)/aspirin 100 mg daily

    Aspirin acts as an irreversible inhibitor of COX-1/-2 enzymes, decreasing prostaglandin precursors formation and inhibiting platelet aggregation. It is the most prescribed medication for cardio-cerebrovascular diseases prevention, as this has been the first antiplatelet with demonstrated effectiveness and safety (Rothlisberger and Ovbiagele, 2015).

  • DrugClopidogrel 75 mg daily

    Clopidogrel works by irreversibly blocking the P2Y12 component of ADP receptors on platelets preventing the activation of GPIIb/IIIa receptor complexes (Rothlisberger and Ovbiagele, 2015).

  • DrugTiclopidine 250 mg twice daily

    Ticlopidine has a mechanism of action similar to Clopidogrel, as it works by irreversibly blocking the P2Y12 component of ADP receptors on platelets preventing the activation of GPIIb/IIIa receptor complexes. However it takes longer time to reach the maximal effect (Rothlisberger and Ovbiagele, 2015).

06

What researchers measure

Primary outcomes

  1. Major Cardiovascular Event at 12 months

    Time to the first occurrence of a composite event comprising ischemic stroke, myocardial infarction, or cardiovascular death within 3 months after randomization. The outcome will be assessed as time to first event (days) and cumulative incidence (percentage of participants experiencing at least one event).

    Time frame: From randomization to 12 months

Secondary outcomes

  1. Major Cardiovascular Events at 3 Months

    Time to the first occurrence of a composite event comprising ischemic stroke, myocardial infarction, or cardiovascular death within 3 months after randomization. The outcome will be assessed as time to first event (days) and cumulative incidence (percentage of participants experiencing at least one event).

    Time frame: From randomization to 3 months

  2. Medication Adherence

    Percentage of participants (%) with good medication adherence, defined as a score ≥20 on the 5-item Medication Adherence Report Scale (MARS-5). Total scores range from 5 to 25, with higher scores indicating better adherence.

    Time frame: At 3 and 12 months after randomization

  3. Platelet responsiveness

    Percentage of participants (%) demonstrating adequate biological response to the ongoing antiplatelet therapy, assessed by multiple electrode aggregometry (Multiplate Analyzer) using the arachidonic acid-induced (ASPI) test for aspirin and the adenosine diphosphate-induced (ADP) test for clopidogrel/ticlopidine. Platelet aggregation is measured in aggregation units (U); adequate response is defined as ASPI \<40 U for aspirin and ADP \<46 U for P2Y12 inhibitors.ocol thresholds.

    Time frame: At 12 months after randomization

  4. Good functional status

    Good functional status is measured at 12 months, being defined and adjudicated according to modified Rankin Scale 0-2. The mRS ranges from 0 (no symptoms) to 6 (death), with lower scores indicating better functional status.

    Time frame: At 12 months after randomization

  5. Incidence of Major Bleeding

    Percentage of participants experiencing at least one major bleeding event, defined according to the International Society on Thrombosis and Haemostasis (ISTH) criteria as fatal bleeding, and/or symptomatic bleeding in a critical area or organ (intracranial, intraspinal, intraocular, retroperitoneal, intra-articular, pericardial, or intramuscular with compartment syndrome), and/or bleeding causing a fall in hemoglobin of 20 g/L or more, or leading to transfusion of 2 or more units of whole blood or red cells. Major bleeding events are a component of the composite safety outcome.

    Time frame: From randomization to 12 months

  6. Incidence of Minor Bleeding

    Percentage of participants experiencing at least one minor bleeding event, defined as any reported bleeding not classified as major according to the International Society on Thrombosis and Haemostasis (ISTH) criteria. Minor bleeding events are a component of the composite safety outcome.

    Time frame: From randomization to 12 months

  7. Incidence of Ischemic Stroke

    Percentage of participants experiencing at least one recurrent ischemic stroke within 12 months after randomization.

    Time frame: From randomization to 12 months

  8. Incidence of Myocardial Infarction

    Percentage of participants experiencing at least one myocardial infarction within 12 months after randomization.

    Time frame: From randomization to 12 months

  9. Incidence of Cardiovascular Death

    Percentage of participants who die from cardiovascular causes within 12 months after randomization.

    Time frame: From randomization to 12 months

  10. Gender differences in the primary and secondary outcomes

    Assessment of differences in the incidence of primary and secondary clinical outcomes between female and male participants, expressed as the percentage of participants experiencing each event in each sex subgroup.

    Time frame: From randomization to 12 months

  11. Prevalence of CYP2C192 and CYP2C1917 Genetic Variants

    Percentage of participants carrying the CYP2C19\*2 (rs4244285) or CYP2C19\*17 (rs12248560) genetic variant, assessed separately among responders and non-responders to antiplatelet therapy. Genotypes will be determined from blood samples using TaqMan SNP genotyping assays.

    Time frame: At Baseline

07

Study locations

3 sites
  • IRCCS Istituto delle Scienze Neurologiche di Bologna - Azienda USL di Bologna
    Bologna, BO 40139, Italy
    • Andrea Zini · Contacta.zini@isnb.it · +390516478810
    • Andrea Zini · Principal investigator
  • Ospedale Civile di Baggiovara
    Modena, MO 41126, Italy
  • Ospedale Bufalini - AUSL della Romagna
    Cesena, 47521, Italy
08

References and documents

Publications

  • Zhou K, Yu S, Li J, Tan Y, Xing S, Chen Y, Ouyang F, Zeng J, Zhang J. High on-treatment platelet reactivity is associated with poor outcomes after ischemic stroke: A meta-analysis. Acta Neurol Scand. 2022 Sep;146(3):205-224. doi: 10.1111/ane.13655. Epub 2022 Jun 2. PubMed 35652290 ↗
  • Xie Z, Guo X, Han L, Wang X, Yan Q, Shu C, Fan Z, Zhao M. Differences in primary and secondary stroke prevention strategies for Chinese men and women. Prev Med Rep. 2023 Apr 26;33:102219. doi: 10.1016/j.pmedr.2023.102219. eCollection 2023 Jun. PubMed 37223569 ↗
  • Weber R, Brenck J, Diener HC. Antiplatelet therapy in cerebrovascular disorders. Handb Exp Pharmacol. 2012;(210):519-46. doi: 10.1007/978-3-642-29423-5_21. PubMed 22918745 ↗
  • Rothlisberger JM, Ovbiagele B. Antiplatelet therapies for secondary stroke prevention: an update on clinical and cost-effectiveness. J Comp Eff Res. 2015 Aug;4(4):377-84. doi: 10.2217/cer.15.22. PubMed 26274799 ↗
  • Rosafio F, Lelli N, Mimmi S, Vandelli L, Bigliardi G, Dell'Acqua ML, Picchetto L, Pentore R, Ferraro D, Trenti T, Nichelli P, Zini A. Platelet Function Testing in Patients with Acute Ischemic Stroke: An Observational Study. J Stroke Cerebrovasc Dis. 2017 Aug;26(8):1864-1873. doi: 10.1016/j.jstrokecerebrovasdis.2017.04.023. Epub 2017 May 30. PubMed 28576652 ↗
  • Del Giovane C, Boncoraglio GB, Bertu L, Banzi R, Tramacere I. Antiplatelet drugs for secondary prevention in patients with ischemic stroke or transient ischemic attack: a systematic review and network meta-analysis. BMC Neurol. 2021 Aug 16;21(1):319. doi: 10.1186/s12883-021-02341-2. PubMed 34399713 ↗
  • Carlsson A, Irewall AL, Graipe A, Ulvenstam A, Mooe T, Ogren J. Long-term risk of major adverse cardiovascular events following ischemic stroke or TIA. Sci Rep. 2023 May 23;13(1):8333. doi: 10.1038/s41598-023-35601-x. PubMed 37221291 ↗
  • Aradi D, Storey RF, Komocsi A, Trenk D, Gulba D, Kiss RG, Husted S, Bonello L, Sibbing D, Collet JP, Huber K; Working Group on Thrombosis of the European Society of Cardiology. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. Eur Heart J. 2014 Jan;35(4):209-15. doi: 10.1093/eurheartj/eht375. Epub 2013 Sep 25. No abstract available. PubMed 24067509 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Dec 2029, 36 months later.

Of 76 non-industry phase 4 interventional studies under Ischemic Stroke, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 42. This study's planned 36 months is above that.

Counting every sponsor, half of 85 studies reached it within 31 months; a quarter within 24 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2026
First posted
Nov 17, 2026
StartEst.
Dec 2026
Primary completionEst.
Dec 2029
CompletionEst.
Jun 2030
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07943026
Lead sponsor
Azienda Usl di Bologna
Responsible party
Sponsor
First posted
Nov 17, 2026
Start date
Dec 2026 (estimated)
Primary completion
Dec 2029 (estimated)
Completion
Jun 2030 (estimated)
Last update
Nov 17, 2026

Study contacts

Andrea Zini
Contact
a.zini@isnb.it
+390516478810
Stefano Forlivesi
Contact
stefano.forlivesi@ausl.bologna.it
+390516478889
Andrea Zini
principal investigator · IRCCS Istituto delle Scienze Neurologiche di Bologna - AUSL of Bologna

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion